PhaseBio Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAS research report →
Price Chart
About the company
PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor.
- CEO
- Jonathan Mow
- IPO
- 2018
- Employees
- 60
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on PHAS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -15.58
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -20.42
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1204.12%
- Net Margin
- -1210.15%
- ROE
- 0.22%
- ROIC
- -0.34%
Latest fiscal year · YoY change
- Revenue
- $10.83K-96.6%
- Gross Profit
- $10.83K+3284.7%
- Op Income
- $-130,418
- Net Income
- $-131,071+99.9%
- EPS
- $-0.00+99.9%
- OCF Growth
- +20.9%
- FCF Growth
- +18.4%
- 52W High
- $4.08
- 52W Low
- $0.04
- 50D MA
- $0.43
- 200D MA
- $0.91
- Beta
- 2.87
- RSI (14)
- 16
- Avg Volume
- 1.79M
No earnings-call transcripts are available for PHAS yet.
of shares held by institutions
43 13F filers
Buy/sell ratio 1.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Johnson & Johnson Innovation - Jjdc, Inc. | 1.61M | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PHAS coverage
Recent articles, reports, and earnings notes.
No research on PHAS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHAS report →PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
businesswire.com · Oct 24
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
businesswire.com · Oct 24
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
247wallst.com · Oct 17
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 12
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
businesswire.com · Aug 12
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
businesswire.com · Aug 12
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
zacks.com · May 16
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
businesswire.com · May 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.